-
Mashup Score: 27
Concurrent chemoradiotherapy (cCRT) is the mainstay of treatment for patients diagnosed with locally advanced non-small cell lung cancer (NSCLC). One significant challenge in the effectiveness of this therapy is the potential development of resistance mechanisms, where autophagy up-regulation has been proposed as a key contributing factor. However, there is a lack of reliable biomarkers to predict outcomes on these patients. Interestingly, for addressing this gap, extracellular vesicles (EVs) and circulating tumor cells (CTCs) have emerged as potential sources of such biomarkers. In this study, we investigated EV-associated miRNAs and presence of autophagic CTCs in prospectively collected serial samples from 38 patients with stage III NSCLC undergoing cCRT. Our findings revealed that non-responders exhibited low levels of baseline EV miR-375, miR-200c, and miR-30c. In particular, EV miR-30c showed high predictive value with an area under the curve of 87.2%. Low EV miR-30c and the prese
Source: biomarkerres.biomedcentral.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41ISLB 2023 - ISLB 2023 - 1 year(s) ago
Welcome to the5th Annual Congress of Liquid Biopsy Christian Rolfo ISLB President It is my greatest pleasure to welcome you all to the 5th Congress of Liquid Biopsy: “Opportunities and Challenges of Liquid Biopsy” (ISLB23) in our beautiful city of Madrid, Spain. Liquid biopsy is a fascinating and exponentially growing field that has a tremendous … ISLB 2023 Read More »
Source: 2023.islb.infoCategories: General Medicine News, Hem/OncsTweet-
Nice collection of #liquidbiopsy papers of @CD_AACR If you’re interested in the field we wait for you at #ISLB23 in Madrid November 19-21 🇪🇸 More info https://t.co/vRM2LCzvcJ @UmbertoMalapel1 @MCristofanill @MJOSESERRANO19 @drgandara @ElJanLe @isliquidbiopsy https://t.co/3EwJf6P9rI https://t.co/8PqE3B9qqJ
-
-
Mashup Score: 2Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer - 1 year(s) ago
Author links open overlay panel Ananda M. Rodilla 1 16, Rajesh M. Valanparambil 2 3 16, Philip C. Mack 1, Chih-Yuan Hsu 4, Jazz Cagan 1, Sooyun C. Tavolacci 1, Juan Manuel Carreño 5 6, Rachel Brody 7, Amy Moore 8, Jennifer C. King 9, Jorge E. Gomez 1, Nicholas Rohs 1, Christian Rolfo 1, Paul A. Bunn Jr. 10, David E. Gerber 11, John D. Minna 11, Florian Krammer 5 6 7, Suresh S. Ramalingam 12, Adolfo García-Sastre 5 7 13 14 15, Yu Shyr 4 … Fred R. Hirsch 1 7 17 This work was supported by NCI SeroNET grant
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6ScienceDirect - 1 year(s) ago
Read the latest articles of The Journal of Liquid Biopsy at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 42023 WCLC Highlights | IASLC - 1 year(s) ago
Dr. Navneet Singh, MD DM (India) will moderate the program and lead the discussion and Q&A following panel presentations by Christian Rolfo, MD, Ph.D., MBA (USA …
Source: www.iaslc.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0ISLB 2023 - ISLB 2023 - 1 year(s) ago
Welcome to the5th Annual Congress of Liquid Biopsy Christian Rolfo ISLB President It is my greatest pleasure to welcome you all to the 5th Congress of Liquid Biopsy: “Opportunities and Challenges of Liquid Biopsy” (ISLB23) in our beautiful city of Madrid, Spain. Liquid biopsy is a fascinating and exponentially growing field that has a tremendous … ISLB 2023 Read More »
Source: 2023.islb.infoCategories: Hem/Oncs, Latest HeadlinesTweet-
Congrats @ValsamoA and all the team for this elegant study! You’re paving the way for ctDNA #liquidbiopsy in IO response! 🚨This and more important insights will be presented by Dr Anagnstou at our Annual ISLB congress in Madrid on 19-21 November! #ISLB23 https://t.co/vRM2LCA32h https://t.co/pYpT8XbRAD
-
-
Mashup Score: 4V Workshop on Genomics in Cancer. Advancing in molecular diagnosis and precision medicine - 1 year(s) ago
V Workshop on Genomics NH Valencia Center, C/ de Ricardo Micó, 1, 46009 Valencia genomicscancer@doctaforum.com We use our own and third party cookies for the correct operation, display and use of the website by the user and to improve our services by collecting statistical data on the navigation of users on the website. You can learn more about the cookies we use and even reject them by viewing our Cookie Policy. By pressing the ‘Accept’ button you consent to the use of the above cookies. Functional
Source: www.doctaforum-events.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6
AbstractPurpose:. Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non–small cell lung cancer (NSCLC); however, a multicenter cohort of patients with EGFR-mutant lung cancers treated with osimertinib and selpercatinib for RET fusion–mediated osimertinib resistance has not previously been published.Patients and Methods:. Patients who received selpercatinib in combination with osimertinib on a prospective expanded access clinical trial (NCT03906331) and single-patient compassionate use programs across five countries were centrally analyzed. All patients had advanced EGFR-mutant NSCLC with a RET fusion detected from tissue or plasma following osimertinib therapy. Clinicopathologic and outcomes data were collected.Results:. Fourteen patients with EGFR-mutant and RET fusion–positive lung cancers who experienced prior progression on osimertinib received osimertinib and selpercatinib. EGFR exon 19 deletions (±T790M, 86%) and non-KIF5B fusi
Source: aacrjournals.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6PULCOR · Oncocor - 1 year(s) ago
Curso multidisciplinario sobre cáncer
Source: pulcor.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer - 1 year(s) ago
Abstract. cfDNA concentrations from patients with cancer are often elevated compared to that of healthy controls, but the sources of this extra cfDNA have never been determined. To address this issue, we assessed cfDNA methylation patterns in 178 patients with cancers of the colon, pancreas, lung, or ovary and 64 patients without cancer. Eighty-three of these individuals had cfDNA concentrations much greater than those generally observed in healthy subjects. The major contributor of cfDNA in all samples was leukocytes, accounting for ~76% of cfDNA, with neutrophils predominating. This was true regardless of whether the samples were derived from patients with cancer or the total plasma cfDNA concentration. High levels of cfDNA observed in patients with cancer did not come from either neoplastic cells or from surrounding normal epithelial cells from the tumor’s tissue of origin. These data suggest that cancers may have a systemic effect on cell turnover or DNA clearance.
Source: aacrjournals.orgCategories: Hem/Oncs, Latest HeadlinesTweet
📣Thrilled to see our paper published open access today! Baseline EVs miRNA-30c & autophagic CTCs predict chemoradiotherapy resistance and outcomes in pts with lung cancer 🫁☢️💉 Here 🧵 with results @ddemiguelperez https://t.co/8kQ7rPJAl2